For The Better

The telehealth powerhouse is heading toward profitability, and patient investors could benefit.

It’s time for Walgreens to make a decision about its dividend.

It’s time for Walgreens to make a decision about its dividend.

These stocks slumped in 2023, but they could bounce back in 2024.

These stocks slumped in 2023, but they could bounce back in 2024.

The “Magnificent Seven” stocks have varying valuations. Four have room to run, and three have gotten too rich.

The “Magnificent Seven” stocks have varying valuations. Four have room to run, and three have gotten too rich.

Is the alternative meat company a buy heading into 2024?

Is the alternative meat company a buy heading into 2024?

These leading brands outperformed the market in 2023, but that’s not why you should buy them.

These leading brands outperformed the market in 2023, but that’s not why you should buy them.

Which of these athletic footwear makers has more room to run?

Which of these athletic footwear makers has more room to run?

This duo could have limited downside and compelling upside ahead.

This duo could have limited downside and compelling upside ahead.

Only three of the seven make the cut as buys at current levels.

Only three of the seven make the cut as buys at current levels.

Yes, you’ll get more checks, but they come at a price.

Yes, you’ll get more checks, but they come at a price.

This popular sector should be on every investor’s radar.